 COPENHAGEN, Denmark, Oct. 14, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS NASDAQ: EVAX Evaxion or the Company, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has been awarded this years Enabling Technology Leadership Award in the artificial intelligence-enabled drug discovery industry by global research and consulting firm Frost Sullivan. The award recognizes Evaxions pioneering spirit towards cutting-edge technology and data-driven decision-making. 